Skip to main content
Evidence Snapshot

Beta-lactamase VIM-2

CHEMBL5798 SINGLE PROTEIN Pseudomonas aeruginosa
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5798
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Beta-lactamase VIM-2 as ChEMBL target CHEMBL5798, mapped to UniProt Q9K2N0. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Beta-lactamase VIM-2
SINGLE PROTEIN · Pseudomonas aeruginosa
As of 2026-09-13
ChEMBL target ID
CHEMBL5798
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q9K2N0
beta-lactamase
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Review-ready Target Rationale

Why Beta-lactamase VIM-2 matters

As of 2026-09-13

Beta-lactamase VIM-2 is reviewed as beta-lactamase (UniProt Q9K2N0); the current evidence base includes 3 approved drugs, 137 compounds, and 46 assays, with lead potency reaching pChEMBL 7.2.

Disease context
Disease signal

Disease relevance is not yet populated for this evidence card.

This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

ChEMBL target record
Activity base
Portfolio and assay base

ChEMBL currently tracks 3 approved drugs, 137 compounds, and 46 assays for this target. The dominant activity type is IC50. CHEMBL4788033 is the current potency anchor at pChEMBL 7.2.

Use CHEMBL4788033 as the tractability anchor when discussing potency (pChEMBL 7.2).

Activity source · ChEMBL 36 via Core Engine
3 approved pChEMBL 7.2
Source Guidance

Start with the right source

Pick the first block or linked source that matches the review question in front of you.

Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution

Start with the review rationale when you need to explain why Beta-lactamase VIM-2 matters before drilling into raw source blocks.

Jump to Review Rationale
Need stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Go back to the target snapshot when you need the naming and mapping contract behind UniProt Q9K2N0, not just the summarized rationale.

Open Protein Context
Need disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.

Open Disease Context

Snapshot State

No project snapshot selected. Export uses the live evidence card state.

137
Total Compounds
46
Total Assays
3
Approved Drugs
IC50: 56.0, KI: 1.0, KD: 12.0
Activity Types

pChEMBL Activity Distribution

Top 5 Inhibitors (by pChEMBL)

Structure Compound pChEMBL Type Phase
No preferred name
CHEMBL4788033
 7.2 IC50 —
No preferred name
CHEMBL4793717
 6.9 IC50 —
No preferred name
CHEMBL4750008
 6.8 IC50 —
No preferred name
CHEMBL4068259
 6.7 IC50 —
No preferred name
CHEMBL4796446
 6.6 IC50 —

Approved Drugs

Structure Compound First Approval
CAPTOPRIL
CHEMBL1560
 1981
← Target Page
Source Header

ChEMBL 36 via Core Engine

Target Snapshot 2026-09-13T22:20:58Z
Source · ChEMBL 36 via Core Engine
ChEMBL ChEMBL 36 CHEMBL5798